Full Press Release Details
Biogen Announces Positive Topline Results from Phase 2 CONVEY Study in Small Fiber Neuropathy.
BIIB
Biogen Announces Positive Topline Results from Phase 2 CONVEY Study in Small Fiber Neuropathy
Key Takeaway: Biogen Announces Positive Topline Results from Phase 2 CONVEY Study in Small Fiber Neuropathy
Price reaction · baseline $299.21 (2021-09-15 close) · hit after-hours · 4 other BIIB headline(s) in the window, move may be shared
day 0 close
+0.2%
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceBest trade, last catalyst
+34%
120-day peak, hindsight
Typical move
1.8%
average across 15 past catalysts
Lead asset
Alefacept
Phase 3 · Chronic Plaque Psoriasis